Skip to main content

Advertisement

SpringerLink
Log in

20-Year prevalence projections for dementia and impact of preventive policy about risk factors

  • NEUROEPIDEMIOLOGY
  • Published:
European Journal of Epidemiology Aims and scope Submit manuscript

Abstract

Incidence of dementia increases sharply with age and, because of the increase in life expectancy, the number of dementia cases is expected to rise dramatically over time. Some studies suggest that controlling some modifiable risk factors for dementia like diabetes or hypertension could lower its incidence. However, as treating these vascular factors would also reduce mortality risk, the actual impact of such public-health intervention on dementia prevalence is not known. Accounting for the impact of dementia and risk factors on mortality, the aim of this work was (1) to compute projections of age- and-sex specific prevalence of dementia in France from 2010 to 2030, (2) to evaluate how public-health interventions targeting risk factors for dementia could change these projections. Age-and-sex specific incidence of dementia and mortality of demented subjects were estimated from the Paquid population-based cohort using a semi-parametric illness-death model. Future global mortality rates and population sizes were obtained from national demographic projections. Under the assumption that life expectancy will increase by 3.5 years for men and 2.8 years for women by 2030, the number of subjects with dementia was estimated to increase by about 75 % from 2010 to 2030 with a 200 % increase after 90 years of age. Therapeutic intervention on the whole population reducing high blood pressure prevalence would lead to a decrease in both dementia incidence rates and mortality and would have a modest impact on the number of dementia cases. On the other hand, a preventive dementia treatment targeting ApoE4 carriers would probably not improve survival and hence would decrease dementia prevalence by 15–25 %.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gallez C. Rapport sur la maladie d alzheimer et les maladies apparentées. Office Parlementaire d’Évaluation des Politiques de Santé, Bibliothèque des Rapports Publics. http://www.assembleenationale.fr/12/rap-off/i2454.asp (2005).

  2. Alzheimer-Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2012;8:131–168.

    Article  Google Scholar 

  3. Polidori MC, Pientka L, Mecocci P. A review of the major vascular risk factors related to alzheimer’s disease. J Alzheimers Dis. 2012;32:521–530.

    Google Scholar 

  4. Barnes DE, Yaffe K. The projected effect of risk factor reduction on alzheimer’s disease prevalence. Lancet Neurol. 2011;10(9):819–828.

    Article  PubMed  Google Scholar 

  5. Brookmeyer R, Gray S, Kawas C. Projections of alzheimer’s disease in the united states and the public health impact of delaying disease onset. Am J Public Health 1998;88(9):1337–1342.

    Article  PubMed  CAS  Google Scholar 

  6. Brookmeyer R, Gray S. Methods for projecting the incidence and prevalence of chronic diseases in ageing populations: application to alzheimer’s disease. Stat Med. 2000;19(11–12):1481–1493.

    Article  PubMed  CAS  Google Scholar 

  7. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of alzheimer’s disease. Alzheimers Dement. 2007;3(3):186–191.

    Article  PubMed  Google Scholar 

  8. Mura T, Dartigues JF, Berr C. How many dementia cases in france and europe? Alternative projections and scenarios 2010–2050. Eur J Neurol. 2010;17(2):252–259.

    Article  PubMed  CAS  Google Scholar 

  9. Joly P, Commenges D, Helmer C, Letenneur L. A penalized likelihood approach for an illness-death model with interval-censored data: application to age-specific incidence of dementia. Biostatistics 2002;3(3):433–443.

    Article  PubMed  Google Scholar 

  10. Ostbye T, Hill G, Steenhuis R. Mortality in elderly Canadians with and without dementia: a 5-year follow-up. Neurology 1999;53(3):521–526.

    Article  PubMed  CAS  Google Scholar 

  11. Jagger C, Andersen K, Breteler MM, Copeland JR, Helmer C, Baldereschi M, et al. Prognosis with dementia in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 supp l5):S16–S20.

    CAS  Google Scholar 

  12. Ramaroson H, Helmer C, Barberger-Gateau P, Letenneur L, Dartigues JF. Prevalence of dementia and Alzheimer’s disease among subjects aged 75 years or over: updated results of the PAQUID cohort. Rev Neurol. 2003;159(4):405–411.

    PubMed  CAS  Google Scholar 

  13. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a delphi consensus study. Lancet 2006;366(9503):2112–2117.

    Article  Google Scholar 

  14. WHO. World health report 2002. Reducing risks, promoting healthy life. Geneva: WHO, 2002. World Health Organization, Geneva, Switzerland, http://www.who.int/whr/2002 (2002).

  15. Duron E, Hanon O. Hypertension, cognitive decline and dementia. Arch Cardiovasc Dis. 2008;101(3):181–189.

    Article  PubMed  CAS  Google Scholar 

  16. Tolppanen AM, Solomon A, Soininen H, Kivipelto M. Midlife vascular risk factors and alzheimer’s disease: evidence from epidemiological studies. J Alzheimers Dis. 2012;32:531–540.

    Google Scholar 

  17. Power MC, Weuve J, Gagne JJ, McQueen MB, Viswanathan A, Blacker D. The association between blood pressure and incident alzheimer disease: a systematic review and meta-analysis. Epidemiology 2011;22(5):646–659.

    Article  PubMed  Google Scholar 

  18. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein e genotype and alzheimer disease. JAMA 1997;278(16):1349–1356.

    Article  PubMed  CAS  Google Scholar 

  19. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al. Apoe and alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011;16(9):903–907.

    Article  PubMed  CAS  Google Scholar 

  20. Tilvis RS, Kähönen-Väre MH, Jolkkonen J, Valvanne J, Pitkala KH, Strandberg TE. Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci. 2004;59(3):M268–M274.

    Article  Google Scholar 

  21. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. Apoe-directed therapeutics rapidly clear {beta}-amyloid and reverse deficits in ad mouse models. Science 2012;335(6075):1503–1506.

    Article  PubMed  CAS  Google Scholar 

  22. Strittmatter WJ. Old drug, new hope for alzheimers disease. Science 2012;335(6075):1447–1448.

    Article  PubMed  CAS  Google Scholar 

  23. Joly P, Touraine C, Georget A, Dartigues JF, Commenges D, Jacqmin-Gadda H. Prevalence projections of chronic diseases and impact of public health intervention. Biometrics 2013;69:109–117.

    Google Scholar 

  24. Keiding N. Age-specific incidence and prevalence: a statistical perspective. J R Stat Soc Series A 1991;154(3):371–412.

    Article  Google Scholar 

  25. Blanpain N, Chardon O. Projections de population 2007–2060 pour la france métropolitaine: méthode et principaux résultats. Document de travail 2010;F1008. http://alexandre.cor-retraites.fr/IMG/pdf/doc-1446.pdf.

  26. Commenges D, Joly P, Letenneur L, Dartigues JF. Incidence and mortality of Alzheimer’s disease or dementia using an illness-death model. Stat Med. 2004;23:199–210.

    Article  PubMed  CAS  Google Scholar 

  27. Gompertz Benjamin. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. Philos Trans R Soc Lond. 1825;115:513–583.

    Article  Google Scholar 

  28. Blanpain N, Chardon O. Projections de population à l’horizon 2060. un tiers de la population âgé de plus de 60 ans. Insee première 2010;1320:1–4.

    Google Scholar 

  29. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (hyvet-cog): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683–689.

    Article  PubMed  CAS  Google Scholar 

  30. Dahlöf B, Hansson L, Lindholm LH, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the swedish trial in old patients with hypertension (stop-hypertension). Lancet 1991;338(8778):1281–1285.

    Article  PubMed  Google Scholar 

  31. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355(9207):865–872.

    Article  PubMed  CAS  Google Scholar 

  32. Winnock M, Letenneur L, Jacqmin-Gadda H, Dallongeville J, Amouyel P, Dartigues JF. Longitudinal analysis of the effect of apolipoprotein e ε 4 and education on cognitive performance in elderly subjects: the paquid study. J Neurol Neurosurg Psychiatry 2002;72(6):794–797.

    Article  PubMed  CAS  Google Scholar 

  33. Law MR, Morris JK, Wald NJ, et al. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338(191):1245–1253.

    Google Scholar 

  34. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, et al. Incidence of dementia and major subtypes in europe: a collaborative study of population-based cohorts. neurologic diseases in the elderly research group. Neurology 2000;54(11 Suppl 5): S10.

    PubMed  CAS  Google Scholar 

  35. Schrijvers EMC, Verhaaren BFJ, Koudstaal PJ, Hofman A, Ikram MA, Breteler MMB. Is dementia incidence declining? Trends in dementia incidence since 1990 in the rotterdam study. Neurology 2012;78(19):1456–1463.

    Article  PubMed  CAS  Google Scholar 

  36. Rocca WA, Petersen RC, Knopman DS, Hebert LE, Evans DA, Hall KS, et al. Trends in the incidence and prevalence of alzheimers disease, dementia, and cognitive impairment in the united states. Alzheimers Dement. 2011;7(1):80–93.

    Article  PubMed  Google Scholar 

  37. Commenges D, Joly P, Gégout-Petit A, Liquet B. Choice between semi-parametric estimators of markov and non-markov multi-state models from coarsened observations. Scand J Stat. 2006;34(1):33–52.

    Article  Google Scholar 

  38. Amieva H, Le Goff M, Millet X, Orgogozo JM, Pérès K, Barberger-Gateau P, et al. Prodromal alzheimer’s disease: successive emergence of the clinical symptoms. Ann Neurol. 2008;64(5):492–498.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

PAQUID is partly funded by IPSEN and Novartis Laboratories.

Author information

Authors and Affiliations

  1. Inserm U897,ISPED, Université Bordeaux Ségalen, 146 rue Léo Saignat, 33076, Bordeaux Cedex, France

    Hélène Jacqmin-Gadda

  2. Université de Bordeaux, ISPED, Centre Inserm U897, 33000, Bordeaux, France

    Hélène Jacqmin-Gadda, Daniel Commenges, Karen Leffondre, Jean-François Dartigues & Pierre Joly

  3. Inserm, ISPED, Centre Inserm U897, 33000, Bordeaux, France

    Hélène Jacqmin-Gadda, Daniel Commenges, Karen Leffondre, Jean-François Dartigues & Pierre Joly

  4. Université de Bordeaux, U708, 33000, Bordeaux, France

    Annick Alperovitch, Claire Montlahuc, Carole Dufouil & Christophe Tzourio

  5. Inserm, U708, 33000, Bordeaux, France

    Annick Alperovitch, Claire Montlahuc, Carole Dufouil & Christophe Tzourio

  6. Inserm, U1018, 94807, Villejuif, France

    Alexis Elbaz

  7. Université Versailles St-Quentin, UMRS 1018, 94807, Villejuif, France

    Alexis Elbaz

  8. Faculté de Médecine Paris-Descartes, 75006, Paris, France

    Joël Ménard

Authors
  1. Hélène Jacqmin-Gadda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annick Alperovitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claire Montlahuc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel Commenges
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Karen Leffondre
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carole Dufouil
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alexis Elbaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christophe Tzourio
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Joël Ménard
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jean-François Dartigues
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Pierre Joly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hélène Jacqmin-Gadda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacqmin-Gadda, H., Alperovitch, A., Montlahuc, C. et al. 20-Year prevalence projections for dementia and impact of preventive policy about risk factors. Eur J Epidemiol 28, 493–502 (2013). https://doi.org/10.1007/s10654-013-9818-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10654-013-9818-7

Keywords

Search

Navigation